ReviewJournal of asthma and allergy2021
Uncontrolled Asthma: Unmet Needs in the Management of Patients.
Review in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies.European journal of clinical pharmacology · 2022Pooled it
- Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).Immunotherapy · 2024Trial
- Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial.Frontiers in immunology · 2024Trial
- Toward Family-Centered Patient Portals for Childhood Asthma Management Among Black Primary Caregivers: Qualitative Interview Study.JMIR pediatrics and parenting · 2026Article
- Article
- A Multidimensional approach to Severe Asthma Management: the need for Pulmonary Rehabilitation among candidates for Biologic Therapy.Frontiers in medicine · 2026Article
- Acupuncture for Persistent Asthma: Protocol for a Randomized, Sham-Controlled Trial with Neuroimaging.Journal of asthma and allergy · 2026Article
- Guideline-based asthma treatment in Asia: Insights from a robust time-in-state model.The journal of allergy and clinical immunology. Global · 2025Article
- Identifying Treatable Traits of Patients with Asthma Prescribed an ICS/LABA: A Descriptive Analytic Database Study in England.Advances in therapy · 2025Article
- Why Every Asthma Patient Tells a Different Story.Journal of clinical medicine · 2025Article
- The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation.Nature reviews. Drug discovery · 2025Review
- Air Pollution Increases Healthcare Utilization Below Safe Thresholds in Individuals With Asthma.Allergy, asthma & immunology research · 2025Article
- Asthma control and opportunities to optimize management and the healthcare provider experience using the AsthmaOptimiser online tool in Dutch general practice: the CAPTURE study.NPJ primary care respiratory medicine · 2025Observational
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Connections and Unmet Needs: Severe Asthma Biologics and Osteoporosis.Biomedicines · 2025Review
- Article
- Evaluation of Polygenic Risk Score for Prediction of Childhood Onset and Severity of Asthma.International journal of molecular sciences · 2024Article
- The potential role of nanobodies in asthma therapy.Frontiers in pharmacology · 2024Review
- Asthma severity: the patient's point of view.European clinical respiratory journal · 2024Article
- Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence.Pulmonary therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent scientific research has provided clinicians with the tools for substantially upgrading the standard of care in the field of bronchial asthma. Nevertheless, satisfactory asthma control still remains an unmet need worldwide. Identifying the major determinants of poor control in different asthma severity levels represents the first step towards the improvement of the overall patients' management. The present review aims to provide an overview of the main unmet needs in asthma control and of the potential tools for overcoming the issue. Implementing a personalized medicine approach is essential, not only in terms of pharmacological treatments, biologic drugs or sophisticated biomarkers. In fact, exploring the complex profile of each patient, from his inflammation phenotype to his preferences and expectations, may help in filling the gap between the big potential of currently available treatments and the overall unsatisfactory asthma control. Telemedicine and e-health technologies may provide a strategy to both optimize disease assessment on a regular basis and enhance patients' empowerment in managing their asthma. Increasing patients' awareness as well as the physicians' knowledge about asthma phenotypes and treatment options besides corticosteroid probably represent the key and more difficult goals of all the players involved in asthma management at every level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.